Ganciclovir pharmacokinetics during renal impairment.

AUTOR(ES)

Lake, K D

RESUMO

Limited information is available concerning the use of ganciclovir (GCV) in patients with severe renal impairment. The pharmacokinetics of GCV were studied in a heart transplant recipient requiring hemodialysis. The total body clearance was calculated to be approximately 5% of that previously reported for patients with normal renal function. GCV was removed by hemodialysis; a single 4-h procedure decreased the concentration in plasma by approximately 50%. GCV can be safely administered to patients with renal insufficiency if concentrations in plasma are monitored.

Documentos Relacionados

• Pharmacokinetics of sparfloxacin in patients with renal impairment.
• Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.
• Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.
• Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.
• Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.